How To Identify And Mitigate Neurologic Aes When Treating With Car-T And T-Cell Engagers

How to identify and mitigate neurologic AEs when treating with CAR-T and T-cell engagers?

Multiple Myeloma Hub

Lymphoma: Overview of Chimeric Antigen Receptor (CAR) T cells

Harvard Medical School Continuing Education

What are the differences between CAR T-cell therapy and bispecific antibodies?

International Myeloma Foundation

Updates in CAR T Cell Therapies

National Cancer Institute

Investigating CAR T-cell therapy in the treatment of MS

Sattva Neelapu, MD, discusses advancements in the management of CAR T-cell therapy AEs

Neurological toxicities associated with chimeric antigen receptor T cell therapy

T-Cell Engagers: targets, challenges and opportunity

VJHemOnc – Video Journal of Hematology & HemOnc

CAR T-Cell Therapy: How Does It Work?

Dana-Farber Cancer Institute

CAR T-Cell Therapy as an Outpatient Treatment Option

CAR T-cell therapy: what clinicians need to know about managing the AEs

VJHemOnc – Video Journal of Hematology & HemOnc

T Cell Engager Antibodies – focus on Hematological Malignancies | Presented by Dr. John Kuruvilla

Princess Margaret Cancer Centre

CAR T-cell Therapy Video

The Leukemia & Lymphoma Society of Canada

CAR T Cell Therapy Explained (Animation) | City of Hope

What You Need To Know About CAR T-Cell Therapy

Sarah Cannon Research Institute

Update on CAR T-Cell Therapy | LRF Webinars

Lymphoma Research Foundation

The Future of Myeloma: Immune Therapy & Targets - Andrew Cowan, MD | MCRT Webcast November 21 (8/10)

HealthTree Foundation

Treating pediatric ALL with chimeric antigen receptor (CAR) T-cell therapy

VJHemOnc – Video Journal of Hematology & HemOnc

What is CAR T-Cell Therapy?

Michigan Medicine

BiTEs in myeloma – when and who?

VJHemOnc – Video Journal of Hematology & HemOnc